Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC gynecological cancer cooperative group study

M. George, V. Scotto, F. Carnino, P. Dodion, W. W. Ten Bokkel Huinink, N. Rotmensz, J. B. Vermorken

Research output: Contribution to journalArticlepeer-review

Abstract

Sixteen patients with advanced ovarian carcinoma were treated with anaxirone (1,2,4-trigycidyl urazol, TGU), 600 mg/m2 every 4 weeks. Anaxirone was the second or later line of therapy. All patients had evaluable tumors and evidence of failure of prior therapy. None of the patients responded. Two had stabilization of the disease for 4 months. In one patient WHO grade 4 leukopenia and grade 4 thrombocytopenia were observed after the second TGU cycle starting on day 41 and persisted until the patient died due to tumor progression (day 50). No patient experienced thrombophlebitis.

Original languageEnglish
Pages (from-to)867-869
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number6
DOIs
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC gynecological cancer cooperative group study'. Together they form a unique fingerprint.

Cite this